Medical oncologist from Perth - Australia. Interested in thoracic oncology, breast cancer, GUs, clinical trials, fast cars (Formula 1) and @werderbremen_en
My home country Scotland 🏴
NO cervical cancer cases detected in vaccinated women following HPV immunisation!
None! Zero!
What a stunning achievement !
The HPV vaccine ie a modern medical miracle!
@RWinayak@montypal
Very impressive results here #ASCO26
Interested in the assumptions/stats behind the planned phase 3 trial. Given the effect in the phase 2 seems so profound why does the sample size need to be so big in the phase 3 (n=750)
Are you going for OS?
Superb presentation by @RWinayak mentee of the amazing @montypal
on microbial dysbiosis as predictor of benefit of microbiome CBM588 when added to ICI in RCC. #ASCO26@ASCO
Very promising clinical outcomes laying the foundation of the ph 3 BIOFRONT trial led by @PBarataMD@SWOG
Kudos to @montypal for opening the frontier of Microbiome's to enhance ICI efficacy in RCC.
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously.
Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here.
This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group.
If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.
@NarjustFlorezMD#ASCO26
The incidence of SqCC in women in China where this study was conducted is about 10% of that in men
The sex difference in this study is based on the incidence in the community studied
You can only recruit from what is available
https://t.co/QYmG1sLhJh
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
As many other oncologists will also attest, we were taught this was a dead end
It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted
And yet here we are, with truly meaningful survival curves👇
Inspiration on multiple levels #ASCO26
This is a moral issue for the oncology community. Were a drug or supportive care intervention to show OS curves like this, it would be SOC, and covered. For far less than costs of new drugs, our society could provide food for our patients. Perhaps our clinics need to do that.
@BalazsHalmosMD#ASCO2026
I don’t understand why Chinese studies get selected for major presentation then get degraded in discussion for only being done in China, particularly when global ph 3 are running in confirmation…
Discussion labouring the point is sadly not helpful
@ASCO
Dr. Caicun Zhou at #ASCO26 with results from phase III OptiTROP-Lung05: first-line sacituzumab govitecan (sac-TMT, TROP2 ADC) + pembro vs pembro for PD-L1+ NSCLC (n=413). Sac-TMT superior with PFS NR vs 6.6m (HR 0.38) with benefit across subgroups.
@lungoncdoc@ASCO We should be calling out the ALKAZAR 1L study
Inferior control arm to best available care. Alectinib can't be justified as just because lorlatinib is not available everywhere.
No reason @nuvalent can't design and fund a first line trial vs lorlatinib
#ASCO26@ALKpositiveINT
It’s astonishing that CROWN 7y update shows mPFS and median time to IC PFS are still NOT REACHED: Surprisingly only 34% needed a DR and 5% TRAE>discontinuation. Current 4th gen trials will be criticised for inadequate control arms. #ASCO26@ALKpositiveINT@BTOGORG
Impressive data on #nextgen#KRAS G12C inhibitor, Elisrasib, at #AACR26. ORR 73.5% with durable responses to >= 3y in treatment naive population! #LCSM@yonsei_u
Dr. @riess_md at #AACR26 updates RMC-9805 (zoldonrasib) in KRAS G12D NSCLC. Very impressive. G12D is a particular need in lung cancer as many patients have no smoking history and do not fare as well with immunotherapy. Zoldonrasib is a mutant selective, RAS(ON) inhibitor.
#AACR26 Zoldonrasib in previously treated KRAS G12D NSCLC with RR 52%, DCR 93%, time to response 1.4m, mDOR not reached with median follow up of 13.1m, mPFS 11.1m, and 73% of pts with ctDNA clearance. Fantastic presentation, exciting drug for our patients!